

Filed: April 17, 2019

Filed on behalf of: Eli Lilly and Company

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ELI LILLY AND COMPANY  
Petitioner

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH  
Patent Owner

---

Case IPR2018-01710 (Patent No. 8,586,045)  
Case IPR2018-01711 (Patent No. 9,884,907)  
Case IPR2018-01712 (Patent No. 9,884,908)<sup>1</sup>

---

**PETITIONER'S OBJECTIONS TO PATENT OWNER'S EVIDENCE**

---

<sup>1</sup> The word-for-word identical paper is filed in each proceeding identified in the caption. For the Board's convenience, citations to the POPR refer to the paper filed in IPR2018-01710 involving Teva's Patent No. 8,586,045.

The Federal Rules of Evidence (“FRE”) generally apply to proceedings before the Board. 37 C.F.R. § 42.62(a). Pursuant to 37 C.F.R. § 42.64(b)(1) and the FRE, Patent Owner Eli Lilly and Company (“Lilly” or “Patent Owner”) submits the following objections to certain exhibits submitted by Petitioner Teva Pharmaceuticals International GMBH (“Teva” or “Petitioner”). These objections apply equally to Petitioner’s reliance on these exhibits in any subsequently filed documents. These objections are timely filed and served within ten business days of the Board’s decision to institute trial in these proceedings.

#### **Exhibit 2001**

To the extent Teva relies on the content of Exhibit 2001 for the truth of the matter asserted, Lilly objects to Exhibit 2001 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

#### **Exhibit 2002**

To the extent Teva relies on the content of Exhibit 2002 for the truth of the matter asserted, Lilly objects to Exhibit 2002 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

#### **Exhibit 2003**

To the extent Teva relies on the content of Exhibit 2003 for the truth of the

matter asserted, Lilly objects to Exhibit 2003 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

#### **Exhibit 2004**

Lilly objects to Exhibit 2004 under FRE 401-403 as lacking relevance to the instituted grounds. Teva relies on Exhibit 2004 and asserts that CGRP<sub>8-37</sub> was identified in 1989. POPR, 6. But Exhibit 2004 does not establish that CGRP<sub>8-37</sub> was first identified in 1989. Thus, this exhibit does not make any fact more or less probable than it would be without this exhibit. Moreover, Exhibit 2004 is unfairly prejudicial, confuses the issues, misleads the factfinder, and/or is a waste of time.

#### **Exhibit 2007**

Lilly objects to Exhibit 2007 as being duplicative of its Exhibit 1052. “A document already in the record of the proceeding must not be filed again, not even as an exhibit or an appendix, without express Board authorization.” 37 C.F.R. § 42.6(d). Thus, this exhibit should be expunged.

#### **Exhibit 2008**

To the extent Teva relies on the content of Exhibit 2008 for the truth of the matter asserted, Lilly objects to Exhibit 2008 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

**Exhibit 2011**

To the extent Teva relies on the content of Exhibit 2011 for the truth of the matter asserted, Lilly objects to Exhibit 2011 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

**Exhibit 2012**

To the extent Teva relies on the content of Exhibit 2012 for the truth of the matter asserted, Lilly objects to Exhibit 2012 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

**Exhibit 2019**

To the extent Teva relies on the content of Exhibit 2019 for the truth of the matter asserted, Lilly objects to Exhibit 2019 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807.

**Exhibit 2021**

To the extent Teva relies on the content of Exhibit 2021 for the truth of the matter asserted, Lilly objects to Exhibit 2021 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807. Lilly further objects to Exhibit 2021 because it lacks proper foundation or

authenticity under FRE 901.

In addition, Lilly objects to Exhibit 2021 under FRE 401-403 as lacking relevance to the instituted grounds. Because Exhibit 2021 does not reflect any knowledge of one skilled in the art at the time of the alleged invention, this exhibit does not make any fact more or less probable than it would be without this exhibit. Moreover, Exhibit 2021 is unfairly prejudicial, confuses the issues, misleads the factfinder, and/or is a waste of time.

### **Exhibit 2022**

To the extent Teva relies on the content of Exhibit 2022 for the truth of the matter asserted, Lilly objects to Exhibit 2022 as inadmissible hearsay (*see* FRE 801 and 802) that does not fall under any exceptions, including FRE 803, 804, 805, and 807. Lilly further objects to Exhibit 2022 because it lacks proper foundation or authenticity under FRE 901.

In addition, Lilly objects to Exhibit 2022 under FRE 401-403 as lacking relevance to the instituted grounds. Teva relies on Exhibit 2022 and asserts that “Merck ultimately discontinued MK-0974.” POPR, 7. Exhibit 2022, which allegedly contains clinical trial search results for MK-0974, does not establish discontinuation of clinical trials for MK-0974. Because Exhibit 2022 does not reflect any knowledge of one skilled in the art at the time of the alleged invention, this exhibit does not make any fact more or less probable than it would be without

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.